Clinical Nuclear Medicine · 2020 · 57 citations · 7 references
MedicineNuclear MedicineOncologyNeuro-oncologyNeuroradiologyTheranosticsBrain TumorsCentral Nervous System TumorsGlioblastomaNeuro-oncologic ImagingNeuro-oncology ImagingRecurrent Brain TumorsGlioblastoma BiomarkersGlioblastoma Drug TherapyGlioblastoma ImagingGlioblastoma Immunotherapy
A 37-year-old man, treated case of left temporal glioblastoma presented with headache, seizures, and progressive right-sided weakness with MRI evidence of recurrence. Exploratory Ga-PSMA PET/CT demonstrated PSMA expression in the recurrent lesion; it was decided to treat this patient with Lu-PSMA-617. After 3 cycles of Lu-PSMA-617, Ga-PSMA PET/CT showed significant reduction in PSMA uptake and regression in size of lesion on MRI with improvement in patient's symptoms and performance status. Lu-/Ga-PSMA theranostics has potential in patients with recurrent glioblastoma multiforme when other therapeutic options are not feasible.
7
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
68Ga–Prostate-Specific Membrane Antigen-11 PET/CT
Jolanta Kunikowska, Radosław Kuliński, Kristoff Muylle et al. · Clinical Nuclear Medicine · 2019 · 65 citations